Key result
Phorbol ester (PMA) increased, while protein kinase C inhibitors reduced SR-BI-mediated HDL lipid uptake in transfected HepG2 cells.
Protein kinase C modulates SR-BI-dependent HDL lipid uptake in hepatocytes, suggesting a regulatory mechanism for reverse cholesterol transport.
PKC modulation of hepatic HDL uptake is hypothesis-generating for reverse cholesterol transport; no clinical implications yet.
SR-BI is a cell surface HDL receptor that mediates selective uptake of the lipid cargo of HDL, an important process in hepatocytes, driving reverse cholesterol transport from cells in the artery wall. To facilitate examination of factors that modulate SR-BI activity in hepatocytes, we have generated fluorescent protein-tagged versions of SR-BI that allow for facile monitoring of SR-BI protein levels and distribution in transfected cells. We show that deletion of the C-terminal cytosolic tail does not affect the distribution of SR-BI in HepG2 cells, nor is the C-terminal cytosolic tail required for SR-BI-mediated uptake of HDL lipids. We also demonstrate that the phorbol ester, PMA, increased, while protein kinase C inhibitors reduced SR-BI-mediated HDL lipid uptake in HepG2 cells. These data suggest that protein kinase C may modulate selective uptake of HDL lipids including cholesterol in hepatocytes, thereby influencing hepatic HDL cholesterol clearance and reverse cholesterol transport.
No takes yet. Share an insight, caveat, or question.
Brunet et al. (2011) studied this question. Protein kinase C modulators (PMA and PKC inhibitors) was evaluated on SR-BI-mediated HDL lipid uptake. Phorbol ester (PMA) increased, while protein kinase C inhibitors reduced SR-BI-mediated HDL lipid uptake in transfected HepG2 cells.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: